iTeos Therapeutics’ (ITOS) “Outperform” Rating Reaffirmed at Wedbush

iTeos Therapeutics is a biopharmaceutical company that focuses on developing and commercializing novel therapies for cancer. The company's lead product candidate is ITOS-101, an oral small molecule inhibitor of PI3Kd, which is currently in phase 2 clinical trials for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

On Wednesday, Wedbush reissued their outperform rating on shares of iTeos Therapeutics NASDAQITOS. In a research note published on the same day, they maintained their $18.00 price objective on the stock, which is down from their prior price objective of $25.00. This suggests that Wedbush believes that the company's stock is undervalued and has potential for growth.

Separately, JPMorgan Chase & Co. decreased their target price on shares of iTeos Therapeutics. However, this does not necessarily indicate a change in their overall view of the company or its prospects. It is possible that they have revised their target price based on new information or market conditions.

Overall, the reaffirmation of the outperform rating by Wedbush and the decrease in JPMorgan Chase & Co.'s target price suggest that there may be some uncertainty around iTeos Therapeutics' future prospects. However, the company's ongoing clinical trials and potential for growth in the cancer drug market could still make it an attractive investment opportunity for some investors.